Nicox S.A. (NICXF)
USD 0.25
(0.0%)
USD 0.25
(0.0%)
| Year | Total Liabilities | Total Liabilities Growth |
|---|---|---|
| 2023 | 31.56 Million EUR | -27.59% |
| 2022 | 43.59 Million USD | -1.81% |
| 2021 | 44.39 Million USD | -12.48% |
| 2020 | 50.72 Million USD | 34.85% |
| 2019 | 37.61 Million USD | 50.84% |
| 2018 | 24.93 Million EUR | 3.74% |
| 2017 | 24.03 Million EUR | -45.62% |
| 2016 | 44.19 Million EUR | -28.73% |
| 2015 | 62.01 Million EUR | 15.36% |
| 2014 | 53.76 Million EUR | 397.96% |
| 2013 | 10.79 Million EUR | 12.54% |
| 2012 | 9.59 Million EUR | -16.62% |
| 2011 | 11.5 Million EUR | -7.55% |
| 2010 | 12.44 Million EUR | -14.46% |
| 2009 | 14.54 Million EUR | -32.5% |
| 2008 | 21.55 Million EUR | 6.44% |
| 2007 | 20.24 Million EUR | 15.72% |
| 2006 | 17.49 Million EUR | 48.91% |
| 2005 | 11.75 Million EUR | 61.51% |
| 2004 | 7.27 Million EUR | 1.44% |
| 2003 | 7.17 Million EUR | 5.3% |
| 2002 | 6.81 Million EUR | 38.8% |
| 2001 | 4.9 Million EUR | 0.0% |
| Year | Total Liabilities | Total Liabilities Growth |
|---|---|---|
| 2023 Q4 | 31.56 Million EUR | 0.0% |
| 2023 Q1 | 36.75 Million EUR | -15.69% |
| 2023 Q2 | 40.08 Million USD | 9.07% |
| 2023 FY | 31.56 Million EUR | -27.59% |
| 2022 Q2 | 40.38 Million EUR | -5.27% |
| 2022 Q4 | 43.59 Million USD | 7.02% |
| 2022 FY | 43.59 Million USD | -1.81% |
| 2022 Q1 | 42.63 Million EUR | 9.16% |
| 2022 Q3 | 40.73 Million EUR | 0.85% |
| 2021 Q3 | 45.23 Million EUR | 7.61% |
| 2021 Q1 | 49.28 Million EUR | 18.88% |
| 2021 Q2 | 42.03 Million EUR | -14.7% |
| 2021 FY | 44.39 Million USD | -12.48% |
| 2021 Q4 | 39.05 Million EUR | -13.66% |
| 2020 Q2 | 53.53 Million EUR | -9.26% |
| 2020 FY | 50.72 Million USD | 34.85% |
| 2020 Q1 | 58.99 Million EUR | 76.07% |
| 2020 Q3 | 48.58 Million EUR | -9.25% |
| 2020 Q4 | 41.45 Million EUR | -14.67% |
| 2019 Q4 | 33.5 Million EUR | -8.26% |
| 2019 FY | 37.61 Million USD | 50.84% |
| 2019 Q3 | 36.52 Million EUR | 37.11% |
| 2019 Q2 | 26.63 Million EUR | -10.85% |
| 2019 Q1 | 29.88 Million EUR | 19.83% |
| 2018 Q3 | 28.94 Million EUR | 16.9% |
| 2018 Q2 | 24.76 Million EUR | -18.82% |
| 2018 FY | 24.93 Million EUR | 3.74% |
| 2018 Q1 | 30.5 Million EUR | 26.91% |
| 2018 Q4 | 24.93 Million EUR | -13.86% |
| 2017 Q4 | 24.03 Million EUR | -15.39% |
| 2017 Q3 | 28.4 Million EUR | -20.53% |
| 2017 Q2 | 35.74 Million EUR | -6.27% |
| 2017 FY | 24.03 Million EUR | -45.62% |
| 2017 Q1 | 38.13 Million EUR | -13.71% |
| 2016 FY | 44.19 Million EUR | -28.73% |
| 2016 Q4 | 44.19 Million EUR | -10.97% |
| 2016 Q3 | 49.64 Million EUR | -18.8% |
| 2016 Q2 | 61.14 Million EUR | -12.2% |
| 2016 Q1 | 69.63 Million EUR | 12.28% |
| 2015 Q3 | 69.21 Million EUR | 19.18% |
| 2015 FY | 62.01 Million EUR | 15.36% |
| 2015 Q4 | 62.01 Million EUR | -10.39% |
| 2015 Q2 | 58.07 Million EUR | -6.91% |
| 2015 Q1 | 62.38 Million EUR | 16.05% |
| 2014 Q3 | 67.84 Million EUR | 764.32% |
| 2014 Q1 | 10.81 Million EUR | 0.19% |
| 2014 Q2 | 7.85 Million EUR | -27.42% |
| 2014 FY | 53.76 Million EUR | 397.96% |
| 2014 Q4 | 53.76 Million EUR | -20.76% |
| 2013 FY | 10.79 Million EUR | 12.54% |
| 2013 Q4 | 10.79 Million EUR | 27.99% |
| 2013 Q3 | 8.43 Million EUR | -1.75% |
| 2013 Q2 | 8.58 Million EUR | 0.68% |
| 2013 Q1 | 8.52 Million EUR | -11.11% |
| 2012 Q3 | 10.5 Million EUR | 5.6% |
| 2012 Q4 | 9.59 Million EUR | -8.66% |
| 2012 FY | 9.59 Million EUR | -16.62% |
| 2012 Q1 | 9.25 Million EUR | -19.57% |
| 2012 Q2 | 9.94 Million EUR | 7.47% |
| 2011 Q3 | 9.4 Million EUR | 1.65% |
| 2011 Q4 | 11.5 Million EUR | 22.39% |
| 2011 Q1 | 9.85 Million EUR | -20.81% |
| 2011 Q2 | 9.24 Million EUR | -6.16% |
| 2011 FY | 11.5 Million EUR | -7.55% |
| 2010 Q3 | 19.11 Million EUR | -9.59% |
| 2010 Q2 | 21.14 Million EUR | 65.95% |
| 2010 Q1 | 12.73 Million EUR | 0.0% |
| 2010 FY | 12.44 Million EUR | -14.46% |
| 2010 Q4 | 12.44 Million EUR | -34.89% |
| 2009 FY | 14.54 Million EUR | -32.5% |
| 2008 FY | 21.55 Million EUR | 6.44% |
| 2007 FY | 20.24 Million EUR | 15.72% |
| 2006 FY | 17.49 Million EUR | 48.91% |
| 2005 FY | 11.75 Million EUR | 61.51% |
| 2004 FY | 7.27 Million EUR | 1.44% |
| 2003 FY | 7.17 Million EUR | 5.3% |
| 2002 FY | 6.81 Million EUR | 38.8% |
| 2001 FY | 4.9 Million EUR | 0.0% |
| Name | Total Liabilities | Total Liabilities Difference |
|---|---|---|
| Bioxytran, Inc. | 3.24 Million USD | -871.442% |
| Eiger BioPharmaceuticals, Inc. | 53.3 Million USD | 40.78% |
| Institute of Biomedical Research Corp. | 421.56 Thousand USD | -7387.997% |
| SQZ Biotechnologies Company | 50.03 Million USD | 36.915% |
| Intellipharmaceutics International Inc. | 12 Million USD | -162.866% |
| Evofem Biosciences, Inc. | 72.47 Million USD | 56.442% |
| Santhera Pharmaceuticals Holding AG | 59.01 Million USD | 46.509% |
| Propanc Biopharma, Inc. | 3.85 Million USD | -719.619% |
| Marizyme, Inc. | 26.67 Million USD | -18.336% |
| Genus plc | 485 Million USD | 93.491% |
| Pharming Group N.V. | 244.07 Million USD | 87.067% |
| Therapeutic Solutions International, Inc. | 2.01 Million USD | -1470.396% |
| CNBX Pharmaceuticals Inc. | 2.51 Million USD | -1154.487% |
| Nymox Pharmaceutical Corporation | 3.8 Million USD | -730.711% |
| ContraFect Corporation | 32.53 Million USD | 2.963% |
| RegeneRx Biopharmaceuticals, Inc. | 3.82 Million USD | -724.71% |
| IMV Inc. | 37.93 Million USD | 16.782% |
| AXIM Biotechnologies, Inc. | 11.77 Million USD | -168.012% |
| ONE Bio Corp. | 27.49 Million USD | -14.807% |
| RVL Pharmaceuticals plc | 77.41 Million USD | 59.225% |
| Mesoblast Limited | 188.44 Million USD | 83.249% |
| MultiCell Technologies, Inc. | 1617.67 USD | -1951286.871% |
| Arno Therapeutics, Inc. | - USD | -Infinity% |
| Emmaus Life Sciences, Inc. | 82.93 Million USD | 61.938% |
| Genscript Biotech Corporation | 1.32 Billion USD | 97.619% |
| Neon Bloom, Inc. | 1.22 Million USD | -2474.349% |
| Mosaic ImmunoEngineering Inc. | 5.14 Million USD | -513.424% |
| Nanobac Pharmaceuticals, Incorporated | 9.58 Million USD | -229.44% |
| Biomind Labs Inc. | 1.49 Million USD | -2006.416% |
| Provectus Biopharmaceuticals, Inc. | 9.04 Million USD | -249.108% |
| Oncotelic Therapeutics, Inc. | 18.4 Million USD | -71.528% |
| Skye Bioscience, Inc. | 14.07 Million USD | -124.321% |
| GlobeStar Therapeutics Corporation | 1.43 Million USD | -2101.538% |
| VioQuest Pharmaceuticals, Inc. | 5.84 Million USD | -440.288% |
| THC Farmaceuticals, Inc. | 142.09 Thousand USD | -22115.419% |
| PsyBio Therapeutics Corp. | 1.98 Million USD | -1493.24% |
| Arch Therapeutics, Inc. | 9.46 Million USD | -233.48% |
| Sienna Biopharmaceuticals, Inc. | - USD | -Infinity% |
| Acro Biomedical Co., Ltd. | 201.11 Thousand USD | -15595.917% |
| Accustem Sciences Inc. | 1.07 Million USD | -2824.931% |
| EV Biologics, Inc. | 2.11 Million USD | -1392.481% |
| Q BioMed Inc. | 8.13 Million USD | -288.138% |
| GB Sciences, Inc. | 5.41 Million USD | -482.68% |
| Alpha Cognition Inc. | 7.16 Million USD | -340.586% |
| CSL Limited | 18.62 Billion USD | 99.83% |
| Agentix Corp. | 2.51 Million USD | -1157.371% |
| American Oriental Bioengineering, Inc. | 118.72 Million USD | 73.411% |
| Enzolytics Inc. | 365.26 Million USD | 91.358% |
| TetraLogic Pharmaceuticals Corporation | - USD | -Infinity% |
| Resverlogix Corp. | 67.39 Million USD | 53.162% |
| Nuo Therapeutics, Inc. | 838.73 Thousand USD | -3663.658% |
| MetaStat, Inc. | - USD | -Infinity% |
| Curative Biotechnology, Inc. | 5.74 Million USD | -449.391% |
| argenx SE | 444.95 Million USD | 92.906% |
| Northwest Biotherapeutics, Inc. | 74.92 Million USD | 57.866% |
| HST Global, Inc. | 593.59 Thousand USD | -5217.954% |
| Enzon Pharmaceuticals, Inc. | 1.71 Million USD | -1741.715% |
| Wesana Health Holdings Inc. | 1.25 Million USD | -2406.923% |
| Halberd Corporation | 728.71 Thousand USD | -4231.848% |
| Endonovo Therapeutics, Inc. | 24.74 Million USD | -27.564% |
| Inhibitor Therapeutics, Inc. | 3.66 Million USD | -761.271% |
| Zenith Capital Corp. | 27.56 Thousand USD | -114401.795% |
| RespireRx Pharmaceuticals Inc. | 11.9 Million USD | -165.2% |
| GeneThera, Inc. | - USD | -Infinity% |
| Sigyn Therapeutics, Inc. | 3.73 Million USD | -745.324% |
| AVAX Technologies, Inc. | 3.99 Million USD | -690.411% |
| WPD Pharmaceuticals Inc. | 680.83 Thousand USD | -4536.519% |
| Cotinga Pharmaceuticals Inc. | 2.71 Million USD | -1064.129% |
| Ember Therapeutics, Inc. | 238.65 Thousand USD | -13127.099% |
| Anthera Pharmaceuticals, Inc. | - USD | -Infinity% |
| Adynxx, Inc. | - USD | -Infinity% |
| NovAccess Global Inc. | 7.86 Million USD | -301.578% |
| Helix BioMedix, Inc. | 66.92 Thousand USD | -47064.906% |
| Capstone Therapeutics Corp. | 50.26 Million USD | 37.198% |
| Kadimastem Ltd | 3.5 Million USD | -800.662% |
| VitaSpring Biomedical Co. Ltd. | - USD | -Infinity% |
| BioStem Technologies, Inc. | 15.9 Million USD | -98.476% |
| Oncology Pharma Inc. | - USD | -Infinity% |
| Reve Technologies, Inc. | 464.69 Thousand USD | -6692.999% |
| Burzynski Research Institute, Inc. | 27.43 Thousand USD | -114969.442% |
| LadRx Corporation | 2.2 Million USD | -1334.519% |
| Cell Source, Inc. | 15.8 Million USD | -99.706% |
| ProtoKinetix, Incorporated | 44.69 Thousand USD | -70526.007% |
| Regen BioPharma, Inc. | 5.45 Million USD | -478.403% |
| Regen BioPharma, Inc. | 5.45 Million USD | -478.403% |
| Affymax, Inc. | 8.87 Million USD | -255.845% |
| Mobile Lads Corp. | 1.31 Million USD | -2303.279% |
| Itoco Inc. | 1.65 Million USD | -1809.505% |
| Rasna Therapeutics, Inc. | 2.05 Million USD | -1438.679% |
| Pathfinder Cell Therapy, Inc. | 6.04 Million USD | -421.855% |
| International Stem Cell Corporation | 5.27 Million USD | -498.2% |
| CytoDyn Inc. | 127.89 Million USD | 75.318% |
| Claritas Pharmaceuticals, Inc. | - USD | -Infinity% |
| NDT Pharmaceuticals Inc. | 41.79 Thousand USD | -75420.945% |
| NanoSphere Health Sciences Inc. | 1.56 Million USD | -1915.288% |
| Qrons Inc. | 1.48 Million USD | -2020.422% |
| Alseres Pharmaceuticals, Inc. | 11.04 Million USD | -185.796% |
| SYBLEU INC | 681.41 Thousand USD | -4532.58% |
| Advanced Proteome Therapeutics Corporation | - USD | -Infinity% |
| Nascent Biotech, Inc. | 808.79 Thousand USD | -3802.972% |
| Rebus Holdings, Inc. | 5.24 Million USD | -502.194% |
| GlobeImmune, Inc. | - USD | -Infinity% |
| ImmunoCellular Therapeutics, Ltd. | 6.1 Million USD | -417.33% |
| Predictive Technology Group, Inc. | - USD | -Infinity% |
| ProText Mobility, Inc. | 625.8 Thousand USD | -4944.191% |
| Cardax, Inc. | - USD | -Infinity% |
| VG Life Sciences Inc. | 4.61 Million USD | -583.694% |
| Kaleido Biosciences, Inc. | - USD | -Infinity% |
| Advaxis, Inc. | 40.99 Million USD | 23.0% |
| Adhera Therapeutics, Inc. | 22.26 Million USD | -41.779% |
| RenovaCare, Inc. | - USD | -Infinity% |
| Regnum Corp. | 2.02 Million USD | -1458.566% |
| Innovation Pharmaceuticals Inc. | 5.47 Million USD | -476.25% |
| Neutra Corp. | 973.52 Thousand USD | -3142.533% |
| Windtree Therapeutics, Inc. | 29.01 Million USD | -8.795% |
| PureTech Health plc | 125.58 Million USD | 74.864% |
| Coeptis Therapeutics, Inc. | 3.75 Million USD | -740.19% |
| IXICO plc | 1.9 Million USD | -1561.166% |
| IntelGenx Technologies Corp. | 20.52 Million USD | -53.768% |
| Gelesis Holdings, Inc. | 103.32 Million USD | 69.449% |
| CSL Limited | 18.62 Billion USD | 99.83% |
| Cellectis S.A. | 249.36 Million USD | 87.341% |